Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency

AIDS

Volumn 13, Issue 1, 1999, Pages 81-87

  Thuret, Isabelle ^a   Michel, Gerard ^a   Chambost, Hervé ^a   Tamalet, Catherine ^a   Giraud, Patricia ^a   Brunet, Corinne ^b   Perrimond, Henri ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Combination therapy; Paediatric hiv; Ritonavir

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; COTRIMOXAZOLE; IMMUNOLOGIC FACTOR; LAMIVUDINE; PENTAMIDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ARTICLE; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; STAVUDINE; ZIDOVUDINE;

EID: 0032991870     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199901140-00011     Document Type: Article

References (28)

1. 1. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
2. 2. Hammer SM, Squires KE, Hughes MD, et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
3. 3. Cameron DW, Heath-Chiozzi M, Danner S, et al.: Randomised placebo-controlled trial of Ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-549.
4. 4. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B: Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997, 11:F107-F111.
5. 5. Monpoux F, Sirvent N, Cottalorda J, Mariani R, Lefbevre JC: Stavudine, lamivudine, and indinavir in children with advanced HIV-1 infection: preliminary experience [letter]. AIDS 1997, 11:1523-1525.
6. 6. Melvin AJ, Mohan KMM, Manns Arcuino LA, Edelstein RE, Frenkel LM: Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997, 16:968-974.
7. 7. Mueller BU, Nelson RP, Sleasman J, et al.: A phase I/II study of the protease inhibitor Ritonavir in children with human immunodeficiency virus infection. Pediatrics 1998, 101:335-343.
8. 8. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994, 43 (RR-12):1-10.
9. 9. Mueller BU, Zuckerman J, Nelson JR, et al.: Update on the pediatric I/II study of the protease inhibitor ritonavir (ABT-538). 4th Conference on retroviruses and opportunistic infections. Washington, DC, January 1997 [abstracts S75, 722].
10. 10. Mofenson LM, Korelitz J, Meyer WA, et al.: The relationship between serum human immunodeficiency virus type 1 RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected children. J Infect Dis 1997, 175:1029-1038.
11. 11. Berger D, Bucher G, Cimoch P, et al.: Measurement of body weight and body cell mass in patients receiving highly active antiretroviral therapy. Program and Abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto, September/October, 1997 [abstract 1-26].
12. 12. Teixeira Ribeiro A, Trylesinski A, Poujade F, Zucman D, Bletry O: Correlation between body weight and plasma viral load in HIV patients treated by protease inhibitor. Program and Abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto, September/October, 1997 [abstract 1-27].
13. 13. Pollack H, Glasberg H, Lee E, et al.: Impaired early growth of infants perinatally infected with human immunodeficiency virus: correlation with viral load. J Pediatr 1997, 130:915-922.
14. 14. Yogev R, Stanley K, Nachman SA, Pelton S, Mcintosh K, Wiznia A for the PACTG 338 Protocol Team. Virologic efficacy of ZDV+3TC vs. D4T+Ritonavir (RTV) vs. ZDV+3TC+RTV in stable antiretroviral experienced HIV-infected children. Program and Abstracts of the 37th International Conference on Antimicrobial Agents and Chemotherapy. Toronto, September/ October, 1997 [abstract LB-6].
15. 15. Pelton SI, Yogev R, Johnson D: Changes in viral load and immunologic markers in children treated with triple therapy including Ritonavir. Program and Abstracts of the 5th conference on Retrovirus and Opportunistic Infections, Chicago, February, 1998 [abstract 234].
16. 16. Febo I, Chantry C, Lugo L: Use of ritonavir in combination with nucleoside reverse transcriptase inhibitor agents in children and adolescents with perinatally acquired HIV infection. Program and Abstracts of the 5th conference on Retrovirus and Opportunistic Infections, Chicago, February, 1998 [abstract 366].
17. 17. Mayaux MJ, Teglas JP, Mandelbrot L, et al.: Acceptability and impact of zidovudine for prevention of mother to child human immunodeficiency virus-1 transmission in France. J Pediatr 1997, 131:857-862.
18. 18. Mackall CL, Fleisher TA, Brown MR, et al.: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143-149.
19. 19. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
20. 20. Li TS, Tubiana R, Calvez V, et al.: Long term immune recovery in CD4 and CD8+ T cells with highly active anti-retroviral therapy. Program and Abstracts of the 5th Conference on Retrovirus and Opportunistic Infections. Chicago, February, 1998 [abstract 172].
21. 21. Wintergerst U, Hoffmann F, Solder B, et al.: Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immuno-deficiency virus. Pediatr Infect Dis 1998, 17:495-499.
22. 22. Molla A, Korneyeva M, Gao Q, et al.: Ordrered accumulation of mutations in HIV protease confers resistance to RITONAVIR. Nature Med 1996, 2:760-766.
23. 23. Burkhardt B, Perez EE, Mueller B, et al.: Emergence of genotypic resistance in HIV-1 protease in children with reduced virus burden and significant immune reconstitution in response to highly active retrovirus therapy. Program and Abstracts of the 5th Conference on Retrovirus and Opportunistic Infections, Chicago, February, 1998 [abstract 168].
24. 24. Butler KM, Husson RN, Balis FM, et al.: Dideoxyinosine in children with symptomatic human immunodeficiency virus infection. N Engl J Med 1991, 324:137-144.
25. 25. Mueller BU, Buttler KM, Stocker VL, et al.: Clinical and pharmacokinetic evaluation of long term therapy with didanosine in children with HIV infection. Pediatrics 1994, 94:724-731.
26. 26. Kempf DJ, Rode RA, Xu Y, et al.: The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
27. 27. Danner SA, Carr A, Leonard J, et al.: A short term study of the safety, pharmacokinetics, and efficacy of Ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
28. 28. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of RITONAVIR, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995, 333:1534-1539.